ArticleAnnals of family medicine2017
Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study.
Article in Annals of family medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain: A Systematic Review.JAMA network open · 2021Pooled it
- Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.Epidemiologic reviews · 2020Pooled it
- Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.Molecular psychiatry · 2019Pooled it
- Article
- Extended-release Injectable Buprenorphine Initiation in the Emergency Department.The western journal of emergency medicine · 2025Article
- Impact of Alternative Ways to Operationalize Buprenorphine Treatment Duration on Understanding Continuity of Care for Opioid Use Disorder.International journal of mental health and addiction · 2024Article
- After the MATE Act: Integrating Buprenorphine Prescribing Into Mainstream Family Medicine Education and Practice.Family medicine · 2024Article
- Do High-Deductible Health Plans Incentivize Changing the Timing of Substance Use Disorder Treatment?Medical care research and review : MCRR · 2023Article
- Buprenorphine and opioid analgesics: Dispensation and discontinuity among accidental overdose fatalities in the Indianapolis metropolitan area, 2016-2021.Journal of substance use and addiction treatment · 2023Article
- Impact Over 3 Years of a Family Medicine-led Addiction Medicine Curriculum for Medical Students.Family medicine · 2023Article
- Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series.Addiction science & clinical practice · 2023Article
- Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2023Article
- Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.The American journal of psychiatry · 2022Article
- Opioid Use Disorder Curriculum: Preclerkship Pharmacology Case-Based Learning Session.MedEdPORTAL : the journal of teaching and learning resources · 2022Article
- Suboxone: History, controversy, and open questions.Frontiers in psychiatry · 2022Review
- A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).Drug safety · 2022Article
- Pilot survey of prescription opioid use patterns and engagement with harm-reduction strategies in emergency department patients.Exploratory research in clinical and social pharmacy · 2021Article
- Article
- Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.Journal of substance abuse treatment · 2020Article
- Baseline Factors Associated with Mortality in Patients Who Engaged in Buprenorphine Treatment for Opioid Use Disorder: a Cohort Study.Journal of general internal medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In France, most cases of opioid use disorder are treated with buprenorphine by general practitioners in private practice. Using reimbursement data of a representative sample of the French population, Echantillon Généraliste des Bénéficiaires, we investigated mortality during periods when patients were in and out of treatment in a cohort of 713 new users of buprenorphine having a mean (SD) follow-up of 4.5 (1.5) years. The mortality rate was 0.63 per 100 person-years (95% CI, 0.40-0.85) overall. In a multivariate Cox regression model, compared with being in treatment, being out of treatment was associated with a markedly increased risk of death (hazard ratio = 29.04; 95% CI, 10.04-83.99). Buprenorphine appears to be a strong protective factor against mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.